Literature DB >> 21284582

Side effects of chemotherapy in musculoskeletal oncology.

Andreas F Mavrogenis1, Panayiotis J Papagelopoulos, Matteo Romantini, Andrea Angelini, Pietro Ruggieri.   

Abstract

With recent advances in medical and orthopedic oncology, radiation therapy and single- or multiple-agent perioperative chemotherapy are currently applied as an essential part of the multidisciplinary treatment to improve disease-free and overall survival of patients with primary and metastatic bone and soft tissue tumors. However, these treatments have led to unwanted complications. A better understanding of the effects of various antineoplastic agents on bone, soft tissue, and organs may provide the basis for the more efficacious use of antiproliferative drugs when fracture healing or allograft incorporation is required. This knowledge may also provide a rationale for concurrent treatment with drugs that protect against or compensate for adverse effects in osseous repair resulting from chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21284582     DOI: 10.1615/jlongtermeffmedimplants.v20.i1.10

Source DB:  PubMed          Journal:  J Long Term Eff Med Implants        ISSN: 1050-6934


  5 in total

1.  Salivary gland second cancer after bone sarcoma treatment.

Authors:  Alessandra Longhi; Costantino Errani; Marco Gambarotti; Christina Ferrari; Jennifer Kreshak; Georgios N Panagopoulos; Andreas F Mavrogenis; Davide Donati
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-07-15

Review 2.  State-of-the-art approach for bone sarcomas.

Authors:  Andreas F Mavrogenis; Andrea Angelini; Christos Vottis; Emanuela Palmerini; Eugenio Rimondi; Giuseppe Rossi; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-05-03

Review 3.  Chemotherapy and Radiation-Associated Cardiac Autonomic Dysfunction.

Authors:  Alexandra E Teng; Benjamin Noor; Olujimi A Ajijola; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2021-01-08       Impact factor: 5.075

4.  Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.

Authors:  Suwit Duangmano; Phorntip Sae-Lim; Apichart Suksamrarn; Frederick E Domann; Pimpicha Patmasiriwat
Journal:  BMC Complement Altern Med       Date:  2012-10-12       Impact factor: 3.659

5.  Chamaejasmine arrests cell cycle, induces apoptosis and inhibits nuclear NF-κB translocation in the human breast cancer cell line MDA-MB-231.

Authors:  Tingting Zhang; Hongyang Yu; Guanglu Dong; Li Cai; Yuxian Bai
Journal:  Molecules       Date:  2013-01-11       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.